Well-Timed QURE Options Flow Appeared Before uniQure FDA News
Some very well-timed options flow showed up in uniQure, $QURE, before FDA news sent the stock sharply higher.
On June 17, uniQure rallied roughly 78% after the FDA told the company that its existing 3-year Phase I/II data for AMT-130, its Huntington’s disease gene therapy candidate, could support a near-term Biologics License Application for accelerated approval. uniQure said it now intends to submit the BLA in the third quarter of 2026.
The main concern was that uniQure might need to run another trial before filing. That would have meant more time, more capital, and a lot more regulatory uncertainty. Instead, the FDA said the company’s 3-year Phase I/II analysis could be acceptable as the primary basis for an accelerated approval filing, while also working with uniQure on the design of a required confirmatory study.
In plain English – the path forward suddenly looked a lot less blocked than it did before.
That is exactly the type of regulatory update that can completely reprice a biotech stock. When a company moves from “possibly needs another trial” to “may be able to file using existing data,” the market often reacts quickly because the timeline, funding risk, and probability of approval all change at once.
What made this more interesting was the options activity ahead of the news. SmartFlow picked up bullish flow in $QURE before the breakout, showing that traders were positioning ahead of the FDA-driven move.
That does not prove anyone knew the news in advance, and it should not be treated as a guaranteed signal. But it is a good example of why unusual options flow matters, especially in biotech names where regulatory catalysts can create outsized moves.
The takeaway is simple -options flow does not predict every catalyst, but it can help traders spot where aggressive positioning is building before the broader market reacts.
For $QURE, the bullish flow came before a major FDA update, and the stock exploded higher once the news confirmed a cleaner path toward AMT-130’s accelerated approval filing.
To track setups like this, SmartFlow helps traders monitor unusual bullish and bearish options flow, institutional-style activity, and market positioning before major moves become obvious on the chart.
This article is for educational purposes only and is not financial advice.